Prognostic Analyses on a Validation Series of Patients with Waldenström's Disease

Launched by FRENCH INNOVATIVE LEUKEMIA ORGANISATION · Jun 12, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding and improving how doctors predict the outcomes for patients with Waldenström's macroglobulinemia (WM), a type of blood cancer. The research aims to refine a scoring system called the International Prognostic Index (IPSSWM), which helps assess a patient's prognosis based on factors like age and blood tests. By gathering information from both current and past patients, the study hopes to enhance treatment decisions and follow-up care, especially for those who may not show symptoms at diagnosis.

To participate in the trial, individuals must be diagnosed with WM and agree to stay in touch for follow-up evaluations until at least 2024. The study is open to all genders, primarily targeting patients aged 65 and older. Participants can expect regular check-ins and assessments as part of the research, which will include both symptomatic patients (those showing symptoms) and asymptomatic patients (those without symptoms) to provide a comprehensive understanding of the disease. This study is crucial for developing better treatment strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with WM, fulfilling the diagnostic criteria defined at the 2nd Workshop on WM.
• • Patient in whom follow-up is available until at least 01/01/2020. Each participating center should not enroll more 10% of patients lost to follow-up.
• • Patient for whom a minimum annual follow-up is planned until 2024.
• • Having given their consent for this study
• Exclusion Criteria:
• • Patient with other chronic lymphoid malignancy. Special attention will be paid to exclude other lymphoplasmacytic proliferations, especially marginal zone lymphoma.
• • Patient with histological transformation in a diffuse large B-cell lymphoma or any other lymphoma at the time of the initiation of the 1st treatment.
• • No consent for this study.